Pharmaceutical Industry and Public Policy in Post-reform India
Regular price
€65.99
A01=Reji K. Joseph
access to essential medicines
Author_Reji K. Joseph
Beta Crystalline Form
bulk
Bulk Drug Manufacturing
Bulk Drugs
Category=JP
Category=KC
Category=KND
Category=V
Ceiling Prices
Data Exclusivity
dosage
Dosage Forms
DPCO
drug
Drug Price Control
drug regulation
drugs
eq_bestseller
eq_business-finance-law
eq_health-lifestyle
eq_isMigrated=1
eq_isMigrated=2
eq_nobargain
eq_non-fiction
eq_society-politics
Essential Commodities Act
firms
health economics
Imatinib Mesylate
IMS Health
IMS Health Data
indian
Indian medicine pricing policy analysis
Indian Pharma Industry
Indian Pharmaceutical
Indian Pharmaceutical Firms
Indian Pharmaceutical Industry
Indian Pharmaceutical Sector
intellectual property law
Ipr Regime
MNC Subsidiary
Neglected Diseases
out-of-pocket health spending
pharmaceutical R&D strategies
pharmaceuticals
price
product
RCA Index
sector
Suven Life Sciences
Tamil Nadu
Trip Agreement
Trip Flexibility
Product details
- ISBN 9780815375999
- Weight: 470g
- Dimensions: 138 x 216mm
- Publication Date: 28 Nov 2017
- Publisher: Taylor & Francis Inc
- Publication City/Country: US
- Product Form: Paperback
Secure
checkout
Fast Shipping
Easy returns
This book examines the impact of economic reforms in India on the pharmaceutical industry and access to medicines. It traces the changing production and trade pattern of the industry, research and development (R&D) preferences and strategies of Indian pharmaceutical firms, patent system alongside pricing policy measures and their shortcomings. It also analyses the public health financing system in India driven largely by out-of-pocket expenditure — about 60 per cent — and characterised by very high share of medicines in total health expenditure.
Reji K. Joseph is Associate Professor at the Institute for Studies in Industrial Development (ISID), New Delhi, India.
